GAMMA Investing’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$76.7K Buy
1,303
+697
+115% +$42.6K ﹤0.01% 2070
2026
Q2
$34.4K Buy
606
+211
+53% +$9.36K ﹤0.01% 2544
2026
Q1
$11.7K Sell
395
-115
-23% -$3.44K ﹤0.01% 2987
2025
Q4
$19.5K Buy
510
+248
+95% +$8.06K ﹤0.01% 2632
2025
Q3
$6.26K Sell
262
-182
-41% -$3.42K ﹤0.01% 3088
2025
Q2
$6.57K Sell
444
-142
-24% -$2.35K ﹤0.01% 3012
2025
Q1
$10.5K Buy
586
+383
+189% +$7.77K ﹤0.01% 2723
2024
Q4
$3.54K Buy
203
+76
+60% +$1.34K ﹤0.01% 3048
2024
Q3
$1.78K Buy
127
+38
+43% +$396 ﹤0.01% 3109
2024
Q2
$732 Buy
89
+59
+197% +$397 ﹤0.01% 3133
2024
Q1
$231 Buy
+30
New +$253 ﹤0.01% 3214

Other funds holding TVTX

GAMMA Investing's TVTX Position: Q3 2026 in Review

GAMMA Investing increased its Travere Therapeutics (TVTX) stake by 115% in Q3 2026, buying an estimated $42.6K and bringing the position to 1,303 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

GAMMA Investing first reported a position in TVTX in Q1 2024 and has held it in 11 quarters since. 251 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • GAMMA Investing held 1,303 shares of Travere Therapeutics worth $76.7K as of Q3 2026.
  • GAMMA Investing bought 697 Travere Therapeutics shares in Q3 2026, an estimated $42.6K.
  • Travere Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2070 holding.
  • GAMMA Investing first reported a position in Travere Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 251 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.